Dr. Thomas Hoeger
Chief Executive Officer

Thomas Hoeger, Ph.D., has been Chief Executive Officer of Apogenix since November 2005. He also oversees the preclinical and clinical development departments at Apogenix. Previously, he worked as a biotech analyst for DZ Bank in Frankfurt, Germany, for five years. From 1997 to 2000, he headed the 'Central Nervous System' research at BASF AG and Knoll AG. During the previous six years, he held various research and management positions at BASF AG.

Following his studies in biology at the Universities of Kiel and Heidelberg as scholar of the German Academic Scholarship Foundation in Germany, and as Fulbright Scholar at the Massachusetts Institute of Technology (MIT) in Cambridge, MA, USA, Dr. Hoeger obtained his Ph.D. in 1991 with highest honors for the doctoral work performed at the German Cancer Research Center (DKFZ) in Heidelberg, Germany. In 2001, he completed his training as Certified European Financial Analyst (CEFA).

Phone:   +49 (0)6221 586080
E-Mail:    This email address is being protected from spambots. You need JavaScript enabled to view it.


Peter Willinger
Chief Financial Officer

Peter Willinger is Chief Financial Officer of Apogenix. He also directs the human resources, legal/IP, quality assurance, and public relations departments at Apogenix. Before joining Apogenix, he was CFO of LION bioscience AG/SYGNIS Pharma AG in Heidelberg, Germany, where he oversaw the finance, investor relations, and corporate development departments. From 1998 to 2004, he was Director Controlling und Vice President Global Finance & Operations at LION bioscience AG. 

Following his studies in business administration at the Baden-Wuerttemberg Cooperative State University Mannheim, Willinger worked as a controller with Rudolf Wild GmbH in Heidelberg, Germany, for eight years before joining the finance department of LION bioscience AG.

Phone:   +49 (0)6221 586080
E-Mail:    This email address is being protected from spambots. You need JavaScript enabled to view it.